PLRX
Pliant Therapeutics Inc

1,674
Loading...
Loading...
News
all
press releases
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Pliant Therapeutics, Inc. - PLRX
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Pliant Therapeutics, Inc. - PLRX INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of...
PR Newswire·7mo ago
News Placeholder
More News
News Placeholder
PLRX Investors Have Opportunity to Join Pliant Therapeutics, Inc. Fraud Investigation with the Schall Law Firm
PLRX Investors Have Opportunity to Join Pliant Therapeutics, Inc. Fraud Investigation with the Schall Law Firm PLRX Investors Have Opportunity to Join Pliant Therapeutics, Inc. Fraud Investigation...
PR Newswire·7mo ago
News Placeholder
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Pliant Therapeutics, Inc. - PLRX
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Pliant Therapeutics, Inc. - PLRX INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of...
PR Newswire·7mo ago
News Placeholder
PLRX Investors Have Opportunity to Join Pliant Therapeutics, Inc. Fraud Investigation with the Schall Law Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Pliant Therapeutics, Inc. (Pliant or the Company) (NASDAQ...
Business Wire·7mo ago
News Placeholder
Buy Rating Affirmed for Pliant Therapeutics Amid Progress in IPF Treatment Trials
Analyst Ed Arce of H.C. Wainwright maintained a Buy rating on Pliant Therapeutics (PLRX Research Report), boosting the price target to $38.00. Ed...
TipRanks Financial Blog·1y ago
News Placeholder
Pliant Therapeutics' Drug Trial Shows Promise In Reversing Lung Fibrosis In Patients
Phase 2a trial results of Pliant Therapeutics' bexotegrast (PLN-74809) for idiopathic pulmonary fibrosis. Reduced lung collagen, improved FVC, and cough severity, signaling potential fibrosis...
Benzinga·1y ago
News Placeholder
Pliant Therapeutics to Participate in Upcoming Investor Events
SOUTH SAN FRANCISCO, Calif., April 02, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology company and leader in the discovery and development of novel...
Globe Newswire·1y ago
News Placeholder
Pliant Therapeutics (PLRX, $14.81) entered Downtrend as Momentum indicator drops below 0 level on Apr 01, 2024
This indicator may be signaling that PLRX's price has further to drop, since it moved below its price 14 days ago. Traders may consider selling the stock, shorting the stock, or exploring put options...
Tickeron - Stocks·1y ago
News Placeholder
Pliant Therapeutics (PLRX, $14.81) Aroon Indicator entered a Downtrend on April 01, 2024.
For the last three days, A.I.dvisor has detected that PLRX's AroonDown red line is above 70 while the AroonUp green line is below 30 for three straight days. This move could indicate a strong...
Tickeron - Stocks·1y ago
News Placeholder
Analysts Set Pliant Therapeutics, Inc. (NASDAQ:PLRX) Price Target at $48.44
Shares of Pliant Therapeutics, Inc. (NASDAQ:PLRX - Get Free Report) have been assigned a consensus recommendation of "Buy" from the ten analysts that are currently covering the firm, Marketbeat.com...
Ticker Report·1y ago

Latest PLRX News

View

Advertisement. Remove ads.

Advertisement. Remove ads.